NEJM 新英格兰医学杂志· Paul M Ridker A. Michael Lincoff Nikolaus Marx Ann Marie Navar Naveed Sattar Katherine R. Tuttle Matthew Budoff Morten Böttcher Matthew A. Cavender Robin P. Choudhury Jan H. Cornel Grzegorz Gajos Issei Komuro K.M.K. Reddy Parvathareddy Roberto Pontremoli José Francisco Kerr Saraiva Iana I. Simova Lance A. Sloan Alejandro López-Suárez Yi-Da Tang Lale Tokgözoğlu Nqoba Tsabedze Konstantinos Tsioufis Subodh Verma Mathias Vrolix Andreas Andersen Florian M.M. Baeres Kathrine Ekström Mads D.M. Engelmann Sofia Gerward G. Kees Hovingh Anders Hvelplund and Vlado Perkovicthe ZEUS Investigators*·· 6 天前AI 评分29
NEJM：IL-6 抑制剂 ziltivekimab 用于动脉粥样硬化性疾病的试验结果
Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease
AI 导读
NEJM 提前在线发表 ziltivekimab 用于动脉粥样硬化性疾病的研究结果。ziltivekimab 为靶向 IL-6 的抑制剂，该文以动脉粥样硬化性疾病为适应症方向。原文仅提供标题与期刊信息，未披露试验分期、样本量及主要终点数据。
来源：NEJM 新英格兰医学杂志 · nejm.org